Background Image
Table of Contents Table of Contents
Previous Page  153 / 1498 Next Page
Information
Show Menu
Previous Page 153 / 1498 Next Page
Page Background

90

Y Ibritumomab tiuxetan

:

Active in Chemorefractory NHL

Chemorefractory

P

= 0.022

Chemosensitive

P

= 0.394

International Workshop

Response Criteria (%)

0

20

40

60

80

100

73%

42%

71%

83%

ZEVALIN (

n

=33)

ZEVALIN (

n

=35)

Rituxan

(

n

=35)

Rituxan

(

n

=31)

Randomized Phase 3 Trial